Payment overview · 2025
General Payments
$438.97
26 reported records · 15 companies
Healthcare provider profile · identity verified
Brian William Luft, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ZANESVILLE, OH · NPI 1063498061
Verified facts
What the public records show
CMS Open Payments records show Brian William Luft, M.D. received $438.97 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 372 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $123.78 | 28.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.62 | 18.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.51 | 6.7% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $22.16 | 5.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.70 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.28 | 4.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.50 | 4.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.50 | 4.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.05 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.80 | 3.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.25 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.14 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.06 | 3.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $15.00 | 3.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.62 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $438.97 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.62 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.62 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $79.80 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.98 | 3 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 372 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 171 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 237 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 329 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 258 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
450 | 106 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
171 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
237 | 60 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
372 | 82 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
237 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
329 | 79 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
258 | 58 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1616 | 436 |
| Amlodipine Besylate | Amlodipine Besylate | 1094 | 312 |
| Losartan Potassium | Losartan Potassium | 1017 | 269 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 938 | 260 |
| Levothyroxine Sodium | Levothyroxine Sodium | 825 | 235 |
| Omeprazole | Omeprazole | 816 | 257 |
| Pantoprazole Sodium | Pantoprazole Sodium | 656 | 183 |
| Metoprolol Succinate | Metoprolol Succinate | 644 | 186 |
| Gabapentin | Gabapentin | 593 | 135 |
| Duloxetine Hcl | Duloxetine Hcl | 549 | 150 |
| Potassium Chloride | Potassium Chloride | 487 | 115 |
| Lisinopril | Lisinopril | 482 | 140 |
| Synthroid | Levothyroxine Sodium | 450 | 106 |
| Furosemide | Furosemide | 420 | 133 |
| Simvastatin | Simvastatin | 374 | 119 |
| Eliquis | Apixaban | 372 | 82 |
| Trazodone Hcl | Trazodone Hcl | 367 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 348 | 103 |
| Metoprolol Tartrate | Metoprolol Tartrate | 347 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 335 | 103 |
| Sertraline Hcl | Sertraline Hcl | 331 | 102 |
| Mounjaro | Tirzepatide | 329 | 79 |
| Carvedilol | Carvedilol | 328 | 79 |
| Valsartan | Valsartan | 323 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 304 | 66 |
| Metformin Hcl | Metformin Hcl | 280 | 93 |
| Ozempic | Semaglutide | 258 | 58 |
| Jardiance | Empagliflozin | 237 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 46 |
| Buspirone Hcl | Buspirone Hcl | 201 | 58 |
| Allopurinol | Allopurinol | 198 | 53 |
| Xarelto | Rivaroxaban | 196 | 38 |
| Alendronate Sodium | Alendronate Sodium | 190 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 48 |
| Farxiga | Dapagliflozin Propanediol | 171 | 43 |
| Repatha Sureclick | Evolocumab | 164 | 39 |
| Spironolactone | Spironolactone | 164 | 42 |
| Montelukast Sodium | Montelukast Sodium | 162 | 43 |
| Klor-Con M20 | Potassium Chloride | 155 | 53 |
| Bupropion Xl | Bupropion Hcl | 147 | 36 |
| Glimepiride | Glimepiride | 146 | 47 |
| Ezetimibe | Ezetimibe | 143 | 41 |
| Mirtazapine | Mirtazapine | 142 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 142 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 69 |
| Atenolol | Atenolol | 130 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 48 |
| Donepezil Hcl | Donepezil Hcl | 118 | 31 |
| Finasteride | Finasteride | 117 | 37 |
| Metformin Hcl Er | Metformin Hcl | 114 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 34 |
| Clonidine Hcl | Clonidine Hcl | 112 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 112 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 110 | 24 |
| Warfarin Sodium | Warfarin Sodium | 102 | 23 |
| Doxepin Hcl | Doxepin Hcl | 101 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 29 |
| Nifedipine Er | Nifedipine | 92 | 24 |
| Enalapril Maleate | Enalapril Maleate | 90 | 24 |
| Prednisone | Prednisone | 86 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 85 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 85 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 27 |
| Meclizine Hcl | Meclizine Hcl | 83 | 37 |
| Nateglinide | Nateglinide | 81 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 72 |
| Januvia | Sitagliptin Phosphate | 80 | 15 |
| Fenofibrate | Fenofibrate | 79 | 16 |
| Lansoprazole | Lansoprazole | 78 | 19 |
| Methylprednisolone | Methylprednisolone | 75 | 71 |
| Colestipol Hcl | Colestipol Hcl | 72 | 29 |
| Memantine Hcl | Memantine Hcl | 72 | 20 |
| Rybelsus | Semaglutide | 70 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 20 |
| Myrbetriq | Mirabegron | 68 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 66 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 33 |
| Meloxicam | Meloxicam | 64 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 20 |
| Tramadol Hcl | Tramadol Hcl | 62 | 50 |
| Irbesartan | Irbesartan | 61 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 60 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 60 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 14 |
| Famotidine | Famotidine | 59 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 20 |
| Labetalol Hcl | Labetalol Hcl | 58 | 11 |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 57 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 56 | suppressed |
| Ondansetron Odt | Ondansetron | 55 | 36 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Vascepa | Icosapent Ethyl | 55 | 12 |
| Alprazolam | Alprazolam | 52 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 33 |
| Trulicity | Dulaglutide | 50 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 11 |
| Torsemide | Torsemide | 48 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 47 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 17 |
| Nystatin | Nystatin | 46 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Novolog Flexpen | Insulin Aspart | 43 | 13 |
| Sucralfate | Sucralfate | 42 | 12 |
| Topiramate | Topiramate | 42 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | 11 |
| Celecoxib | Celecoxib | 35 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 16 |
| Atrovent Hfa | Ipratropium Bromide | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Nexletol | Bempedoic Acid | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | 13 |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | 13 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 18 |
| Klor-Con M10 | Potassium Chloride | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Tadalafil | Tadalafil | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 20 |
| Primidone | Primidone | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Baclofen | Baclofen | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Levoxyl | Levothyroxine Sodium | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Tirosint | Levothyroxine Sodium | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Tymlos | Abaloparatide | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $438.97 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Flexitouch Plus, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, Nimbl, OTEZLA, Ozempic, QULIPTA, REPATHA, Symbravo, UBRELVY, UNITHROID, ZENPEP, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error